Ozempic

ApprovedSmall molecule

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Ozempic is one of 208 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

207

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Alcoholic Fatty Liver DiseaseActive, not recruiting

Bone FractureActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Pancreatic CancerActive, not recruiting

Type 2 DiabetesActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Bone FracturePhase 1/Phase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Ozempic

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Approved

1 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Medrol

Pfizer

Preclinical

1 5

Byetta

AstraZeneca

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

ABI-007

Bristol-Myers Squibb

Preclinical

2 8

Active Comparator

Moderna

Preclinical

1 9

LDE225

Novartis

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Recruiting

Cardiovascular Disease

NCT06967389

Q1 2029

Phase 3Not yet recruiting

Type 2 Diabetes

NCT07046273

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

Completed·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT06739044·494 enrolled

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Not yet recruiting·SShandong New Time Pharmaceutical Co., LTD·Phase 3·NCT07046273·496 enrolled

Cardiovascular Disease1 trial

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

Recruiting·JJohn Bauer··NCT06967389·50 enrolled

Pancreatic Cancer1 trial

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Unknown status· Novo Nordisk logo

Novo Nordisk··NCT04572165·600,000 enrolled

Bone Fracture1 trial

The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture

Unknown status·MMorten Frost·Phase 1/2·NCT04702516·64 enrolled

Alcoholic Fatty Liver Disease1 trial

Semaglutide in Nonalcoholic Fatty Liver Disease

Completed·ZZagazig University·Phase 4·NCT05813249·180 enrolled

3 more indications

Immunogenicity1 trial

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

Completed·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06634927·68 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06161844·506 enrolled

Biosimilarity1 trial

Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

Completed·GGeropharm·Phase 1·NCT06497049·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Ozempic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ozempic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ozempic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Ozempic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Trials by Indication[1]

Type 2 Diabetes2 trials

Cardiovascular Disease1 trial

Pancreatic Cancer1 trial

Bone Fracture1 trial

Alcoholic Fatty Liver Disease1 trial

Immunogenicity1 trial

Type 2 Diabetes Mellitus1 trial

Biosimilarity1 trial

References

Drug Info

Quick Facts

Related News